Small molecule therapeutic that aims to treat Alzheimer’s patients Verified listing

Small molecule therapeutic that aims to treat Alzheimer’s patients Verified listing

Indicaton

Alzheimer’s disease

Therapeutic indications

Type of product

Small molecule

Table

Phase

Discovery
Partnering status

Not partnered

You may also be interested in

Proclarix

Proclarix® is CE marked, intended for in vitro diagnostic use and indicated for prostate cancer diagnosis in patients with normal digital rectal exam (DRE), enlarged prostate volume and elevated levels of PSA at 2-10 ng/ml.

Marketed

Breast cancer screening test

Xemperia flag-ship project is a PCR-based blood test for breast cancer screening.
The technology can be adapted to other cancers, immune, inflammatory and cardiovascular diseases.
Xemperia's pipeline also includes DNA based nansensors for the ultrasensitive detection of nucleic acids.

Phase II completed

nizubaglustat

Has the potential to treat multiple rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses, and Niemann-Pick disease type C (NPC).

Phase II started